26th week of 2009 patent applcation highlights part 40 |
Patent application number | Title | Published |
20090162390 | Molecular Scaffolds for HIV-1 Immunogens - Methods and compositions are provided which employ chimeric polypeptides having at least one heterologous epitope for a human immunodeficiency virus type 1 (HIV-1) neutralizing antibody. These chimeric polypeptides behave as molecular scaffolds which are capable of presenting the various heterologous HIV-1 epitopes. The invention demonstrates that a heterologous epitope recognized by the HIV-1 neutralizing antibody can be more fully exposed to neutralizing antibodies when presented within the backbone of the chimeric polypeptide than when the epitope is presented within the context of an HIV-1 backbone. Polynucleotides encoding these chimeric polypeptides are also provided. Immunogenic compositions are provided which comprise a chimeric polypeptide having at least one heterologous epitope that interacts with an HIV-1 neutralizing antibody. Immuno genie compositions comprising chimeric polynucleotides encoding the chimeric polypeptides of the invention are also provided. Vaccines comprising such immunogenic compositions are also provided. Further provided are methods which employ the immunogenic compositions of the invention. Such methods include, for example, methods for eliciting an immune response in a subject, methods for generating antibodies specific for the chimeric polypeptide or the chimeric polypeptide, and methods for inhibiting or preventing infection by HIV-1 in a subject. | 2009-06-25 |
20090162391 | VACCINE ANTIGENS FROM PISCIRICKETTSIA SALMONIS - The present invention discloses novel proteins, e.g., antigens, from | 2009-06-25 |
20090162392 | MUTANT FORMS OF STREPTOLYSIN O - Forms of GAS25 (streptolysin O) which are not toxic but which still maintain the ability to induce protection against | 2009-06-25 |
20090162393 | Vaccine composition and uses thereof - The present invention provides a vaccine composition including a nucleic acid that encodes an amoeba-derived antigen (or a peptide molecule encoded thereby), or fragments or variants thereof. The present invention also provides for the use of such vaccine compositions in eliciting an immune response and/or protective immunity in a host against amoebic infection and screening a sample for the presence of amoebae. | 2009-06-25 |
20090162394 | VACCINE - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent | 2009-06-25 |
20090162395 | VACCINE FOR RSV AND MPV - The present invention is directed to alphavirus vectored vaccine contructs encoding paramyxovirus proteins that find use in the prevention of respiratory syncytial virus or human metapneumovirus infections. In particular, these vaccines induce cellular and humoral immune responses that inhibit RSV. Also disclosed are improved methods for producing alphavirus vectored paramyxovirus vaccines. | 2009-06-25 |
20090162396 | gM-NEGATIVE EHV-MUTANTS WITHOUT HETEROLOGOUS ELEMENTS - The present invention relates to the field of animal health and in particular of Equine Herpes Viruses (EHV) wherein the gene encoding the protein gM is absent, and which is free of heterologous elements. Further aspects of the invention relate to pharmaceutical compositions comprising said viruses, uses thereof, and methods for the prophylaxis and treatment of EHV infections. The invention also relates to pharmaceutical compositions comprising the combination of EHV-1 and EHV-4 viruses wherein the gene encoding the protein gM is absent and which is free of heterologous elements. | 2009-06-25 |
20090162397 | HEAT TREATED BACTERINS, AND EMULSION VACCINES PREPARED FROM SUCH HEAT TREATED BACTERINS - Heat treated bacterins, a method of producing heat treated bacterins, and porcine emulsion vaccines prepared from such heat treated bacterins are disclosed. | 2009-06-25 |
20090162398 | Methods and Compositions for Immunizing Pigs Against Porcine Circovirus - The present invention relates to the isolation and identification of two new strains of type 2B porcine circovirus. These two new strains of porcine circovirus may be used for the preparation of vaccine or immunogenic compositions for immunizing pigs against postweaning multisystemic wasting syndrome (PMWS). Accordingly, the invention provides methods for eliciting a protective immune response against a pathogenic porcine circovirus by administering to a pig an immunogenically effective amount of a type 2B porcine circovirus vaccine or immunogenic composition comprising at least one of the porcine circoviruses having a nucleic acid sequence as set forth in SEQ ID NOs: 1 or 2, or at least one protein from at least one of the two new type 2B strains of porcine circovirus as described herein. The invention further relates to protection of a pig from any one or more of the symptoms or sequelae associated with PMWS. | 2009-06-25 |
20090162399 | Nef deleted human immunodeficiency virus for the restoration of T-lymphocyte signaling and activation for the treatment and prevention of human immunodeficiency virus infection - A therapeutic suspension for the treatment of human immunodeficiency virus type I (HIV-1) infection in humans using isolated and purified HIV-1 nef-deficient viral particles having a nef-deletion between the endonuclease cleavage sites Nco I and Xho I. | 2009-06-25 |
20090162400 | Compositions of influenza viral proteins and methods of use thereof - Compositions, fusion proteins and polypeptides comprise at least one pathogen-associated molecular pattern and at least a portion of at least one integral membrane protein of an influenza viral antigen. The compositions, fusion proteins and polypeptides are used to stimulate an immune response in a subject. | 2009-06-25 |
20090162401 | Streptococcus Iniae Phosphoglucomutase is a Virulence Factor and Target for Vaccine Development - The present invention relates generally to the identification of virulence factors from | 2009-06-25 |
20090162402 | IMMUNIZING COMPOSITIONS AND METHODS OF USE - The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions. | 2009-06-25 |
20090162403 | Process for producing an allergen extract - The present invention relates to a process for producing an allergen extract from a biological allergen source material comprising the steps of
| 2009-06-25 |
20090162404 | Tumor vaccine - The invention provides a tumor cell genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen. The invention also provides a method of stimulating an immune response to a tumor by administering an allogeneic tumor cell such as a lung cancer cell genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen. The invention additionally provides a method of inhibiting a tumor by administering an allogeneic tumor cell such as a lung cancer cell genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen. | 2009-06-25 |
20090162405 | Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells - A harmless cancer vaccine is made from cancer cells with extracellular proteins including self-recognition molecular patterns being digested by a proteinase. The cancer vaccine is used to vaccinate an individual to induce immune responses against cancer cells systemically. Cancer cells become harmless when they are digested by Tumorase™. Some proteinases including trypsin cannot kill cancer cells completely and treated cancer cells need to be further processed in order to be harmless and effective. Cancer cells may be from tissue-cultured human or animal cancer cell lines or cancer patients directly. Cancer vaccine vaccinated individuals produce cancer vaccine specific immune responses against cancer cells. Immune response components may be isolated and used to fight against cancer for a cancer patient with a suppressed immune system. Cancer vaccine specific immune components may include cancer vaccine specific polyclonal antibodies, B-cells, T-cells, natural killer cells, monocytes, macrophages and other lymphocytes. | 2009-06-25 |
20090162406 | WOUND HEALING WITH ZEOLITE-BASED HEMOSTATIC DEVICES - A method for decreasing the time it takes for a wound to heal includes applying hemostatic agent to the wound, inflaming tissue surrounding the wound to facilitate the deposition of fibroblast, thereby accelerating the subsequent contraction of the wound and the onset of the proliferative healing stage, and causing the re-epithelization of the tissue at a faster rate than if no hemostatic agent was applied. A method for promoting the healing of a bleeding wound includes coating a hemostatic agent onto a substrate, applying the substrate to the bleeding wound so that an effective amount of the hemostatic agent is applied to the wound, inflaming the tissue, and causing the re-epithelization of the tissue at a faster rate than if no hemostatic agent was applied. In at least some methods, a clotting cascade and platelet aggregation within the bleeding wound is accelerated, and blood loss from the wound is decreased. | 2009-06-25 |
20090162407 | PROCESS FOR PREPARING MICROPARTICLES HAVING A LOW RESIDUAL SOLVENT VOLUME - The disclosed processes for forming microparticles utilize low volumes of processing water while still providing microparticles having low residual solvent levels. The processes are adaptable to both continuous and batch processes using oil/water or water/oil or water/oil/water or oil/water/oil emulsions. | 2009-06-25 |
20090162408 | COMPOSITIONS CONTAINING CATIONICALLY SURFACE-MODIFIED MICROPARTICULATE CARRIER FOR BENEFIT AGENTS - A coated microparticulate composition comprising a microparticulate; wherein the microparticulate comprises a benefit agent; and wherein the microparticulate is coated with: a Type-1 Polymer, wherein the Type-1 Polymer comprises a cationic polymer with a cationic atom content greater than about 3 wt. % and a weight average molecular weight less than about 800,000 Dalton; and a Type-2 Polymer, wherein the Type-2 Polymer comprises a cationic polymer with a cationic atom content less than about 3 wt. % and a weight average molecular weight greater than about 1,000,000 Dalton. | 2009-06-25 |
20090162409 | Microencapsulated Pesticide - A microcapsule can be produced readily by (a) pulverizing a solid pesticidal compound in terpineol, dihydroterpineol, terpinel acetate, dihydroterpinel acetate or a mixture thereof to form a suspension, (b) mixing the resulting suspension and water to prepare a liquid droplet, and (c) forming a coating film of a resin around the liquid droplet. The microcapsule obtained by such a method contains most of the solid pesticidal compound within the microcapsule. | 2009-06-25 |
20090162410 | Process for preparing fine particle dispersion for wood preservation - The present invention provide a method for producing micronized solid particles through a two-step process. The solid particles of the invention comprise metals or metal compounds, especially copper and copper compounds. The solid particle of the invention further comprise organic biocides. The invention further provides a wood preservative composition and wood comprising the solid particles of the invention, which may be diluted to the target concentration with or without addition of a co-biocide and vacuum/pressure impregnated into a variety wood species including refractory wood species to effectively preserve the material from fungal and insect attack. | 2009-06-25 |
20090162411 | ENCAPSULATED KIDNEY TISSUE - Provided are therapeutic implants comprising renal tissue encapsulated within a polymer bead. Also disclosed are methods for treating a disease state in a subject comprising implanting within said subject a therapeutic implant comprising renal tissue encapsulated within a polymer bead. Also provided are methods for making a therapeutic implant comprising: providing renal tissue; mixing the renal tissue with a solution comprising a polymer, thereby forming a tissue-polymer suspension; extruding the tissue-polymer suspension into an bead-forming solution, thereby forming a therapeutic implant comprising beads of said polymer within which the renal tissue is encapsulated. | 2009-06-25 |
20090162412 | IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST - The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time. Dopamine agonist is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with dopamine agonist. | 2009-06-25 |
20090162413 | COMPOSITIONS AND METHODS OF ADMINISTERING RAPAMYCIN ANALOGS WITH PACLITAXEL USING MEDICAL DEVICES - Systems and compositions comprising paclitaxel and a second drug, such as rapamycin, analogs, derivatives, salts and esters thereof are disclosed, as well as methods of delivery wherein the drugs have effects that complement each other. Medical devices comprising supporting structures capable of including or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient can contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating including the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs. | 2009-06-25 |
20090162414 | Foamed ceramics - A method for the production of a macroporous ceramic foam, wherein: (a) forming a ceramic slip comprising a substantially homogeneous mixture of a ceramic particulate, an organic binder in a liquid carrier, and optionally one or more surfactants, wherein at least one surfactant is present if the organic binder does not function as a surfactant, and wherein the ceramic slip preferably has a viscosity in the range of from 15 to 200 mPas | 2009-06-25 |
20090162415 | Gel Scaffolds for Tissue Engineering - The present invention discloses a colloid scaffolds for tissue engineering, comprising collagen and hyaluronic acid (HA). The collagen and the hyaluronic acid (HA) are mixed to form colloidal suspension. The ratio of the collagen and the hyaluronic acid is less than or equal to 300, and the best is less than or equal to 200. The colloidal scaffolds more comprises micro-fibers or nano-fibers which are used to enhance cell attachment and increase the strength of colloid scaffolds and reduce water loss and contraction of colloid scaffolds. | 2009-06-25 |
20090162417 | DRUG ELUTING OCULAR CONFORMER - A coated, drug eluting ocular conformer includes an ocular conformer and at least one substantially purified anti-fibrosis agent. The ocular conformer is formed from a base material having inner and outer sides, including apical and basal portions configured to contact one or more conjunctival tissues in an eye of a patient. The anti-fibrosis agent is formulated into at least one ophthalmic medicament layer over at least one side of the ocular conformer or is impregnated within the base material of the ocular conformer. The device may be configured to release the anti-fibrosis agent from one or both sides of the ocular conformer. An elution control layer may be included to facilitate controlled release of the anti-fibrosis agent. In addition, an adhesion promoting layer may be included in the device to promote adhesion of polymeric layers to the base material or to ocular tissues during delivery. The coated, drug eluting ocular conformer may be used to reduce scarring in the eye, typically by applying the device to the eye following eye surgery, an eye injury caused by chemical, thermal or mechanical trauma, or an eye disease or condition associated with scarring. | 2009-06-25 |
20090162418 | INDICIA-BEARING PACKAGE FOR DELIVERY SYSTEMS FOR MANAGING RELEASE OF FLAVORS IN AN EDIBLE COMPOSITION - A package assembly for supporting a delivery system for inclusion in an edible composition is disclosed. The edible composition is formulated to have at least one ingredient encapsulated with an encapsulating material. The delivery system and the resulting edible composition may include other ingredients to create a desired release profile for the at least one ingredient, any of which can be indicated by indicia on the assembly. | 2009-06-25 |
20090162419 | Live bacteria product - A live bacteria product including dormant viable bacteria suspended in a liquid carrier. The carrier contains mineral oil and polymers and may also include an adsorbent. The product is stored and shipped in a plastic bag and is sprayed onto livestock feed or the like. The treated livestock feed is then fed to the livestock with the ambient moisture in the digestive system of livestock causing the hydration of the bacteria to begin the bacteria's life cycle. | 2009-06-25 |
20090162420 | Matrix-Controlled Transdermal System Comprising Salts of ACE Inhibitor Dicarboxylic Acids - The invention relates to a salt of an ACE inhibitor dicarboxylic acid with an organic amine and/or an alkali compound, a transdermal therapeutic system comprising the salt, and a method of producing the transdermal therapeutic system. | 2009-06-25 |
20090162421 | DRUGS AS WELL AS THEIR PRODUCTION AND USE IN THE TREATMENT OF PAIN-ASSOCIATED NEUROPATHIES - The present invention relates to the use of tarenflurbil and/or a pharmaceutically tolerable salt or derivative thereof in enantiomerically-pure and/or essentially enantiomerically-pure form or a form that is enriched with respect to flurbiprofen racemate and/or a racemate of said salt or derivative, for the production of a drug for the treatment of pain-associated neuropathy, pain-associated neuropathy that is simultaneously accompanied by states of nociceptive pain, peripheral and/or predominantly peripheral neuropathic pain or central and/or predominantly central neuropathic pain. | 2009-06-25 |
20090162422 | Single-domain brain-targeting antibody fragments derived from LLAMA antibodies - A phage-displayed library of llama single heavy domain antibodies (sdAbs) was enriched for species that selectively bind to and are internalized by human cerebromicrovascular endothelial cells (HCEC). From the enriched library, two sdAbs were selected, sequenced, subcloned, and expressed as fusion proteins with c-myc-His | 2009-06-25 |
20090162423 | Formulations for cosmetic and wound care treatments with photosensitizes as fluorescent markers - Photoactive materials, such as photosensitizers, are used as fluorescent markers for in vivo detection of the distribution of the injected filler material during cosmetic treatments. In one preferred embodiment, liposomal formulated temoporfin is used, as the photoactive component, in very small concentrations along with fillers for cosmetic and wound healing applications. Fillers, which can be used in the invention, include collagen, hyaluronic acids and other synthetic or natural products which are generally used in wound healing, scar reduction and other such medical applications. In a preferred embodiment, the formulated photosensitizer is coupled to the filler so that tracking is possible over longer periods of time A liposomal formulated photosensitizer is injected with the fillers into the treatment area, and is irradiated with laser light shortly after injection. The emitted fluorescence is measured by a special non-invasive device. Thereby it is possible to monitor the injection site and the distribution of the injected solution around the injection site. When irradiated with laser or other light source, the fluorescence of the photosensitizer is detected using a fluorescence detector, which permits tracking the filler at injection site and in the injection volume. | 2009-06-25 |
20090162424 | COMPOSITIONS AND METHODS FOR MAKING AND USING MULTIFUNCTIONAL POLYMERIZED LIPOSOMES - According to some embodiments, the present invention provides compositions and methods for making and using multifunctional polymerized liposomes finding relevant application in medical sciences, particularly in bioimaging, diagnostics, drug delivery, and drug formulation. The compositions and methods involve lipids that are both polymerizable and have a “clickable” group that provides the ability to functionalize via a click reaction with various functional moieties useful for the above-listed applications. | 2009-06-25 |
20090162425 | METHODS AND COMPOSITIONS FOR INHIBITING UNDESIRABLE CELLULAR PROLIFERATION BY TARGETED LIPOSOME DELIVERY OF ACTIVE AGENTS - Provided are methods for inhibiting undesirable proliferation of a tumor cell or a tumor in a subject including administering to the subject a composition that includes an effective amount of an active agent, wherein the active agent is entrapped by one or more liposomes, the active agent has activity in inhibiting undesirable proliferation of the tumor cell or the tumor, and the one or more liposomes include one or more targeting agents that preferentially or specifically bind to a binding molecule expressed by the tumor cell or the tumor, present on the tumor cell or the tumor, present in the tumor cell or the tumor, or combinations thereof. Also provided are compositions for treating tumors, particularly gliomas, in a subject in need thereof. | 2009-06-25 |
20090162426 | Use of a Compound with RANKL Activity - The present invention relates to the use of a compound with receptor activator of nuclear factor-kB ligand (RANKL) activity for the manufacture of a topical pharmaceutical formulation for the modulation of local or systemic Treg numbers and the treatment or the prevention of skin-associated or systemic diseases. | 2009-06-25 |
20090162427 | VACCINES USING NUCLEIC ACID-LIPID COMPLEXES - This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method. | 2009-06-25 |
20090162428 | Immediate disintegration polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof - An immediate disintegrating polymeric matrix for oral administration with modified release is disclosed, obtained without using inert supports such as sugar spheres, comprising particles of active substance directly covered with a release regulating membrane. Use of such a matrix to prepare various administration forms for oral use as well as the method of its preparation are also disclosed. | 2009-06-25 |
20090162429 | Slow-Release Composition, Method for the Preparation Thereof, and Use Thereof - The pharmaceutical or nutraceutical composition with sustained release of an active ingredient according to the present invention comprises at least one coated granule; the coated granule being composed of a particle that comprises said active ingredient and is coated with at least two coatings that comprise a combination of excipients. The present invention relates also to a process for the preparation of the composition. | 2009-06-25 |
20090162430 | Gelatin Capsule With Extra Cap for Combined Therapies - A new pharmaceutical dosage form for the administration of combined therapies without interaction between them is disclosed. It consists of an upper gelatin capsule, hard or soft, with extra lower hard gelatin cap. The upper capsule contains one or more biologically active agent and the lower hard gelatin cap contains other biologically active agent or agents. Other lower or upper caps could be added to said capsule containing other biologically active agents with the same principle. | 2009-06-25 |
20090162431 | Sustained release formulations containing acetaminophen and tramadol - The present invention provides a pharmaceutical dosage form for sustained release of a combination of acetaminophen and tramadol or its salts. The dosage form has an immediate release portion and a sustained release portion. The immediate release portion has about 16%-75% of the drugs. The sustained release portion includes: a. about 25%-84% of the drugs, at least one gelling polymer in an amount by weight of the total formulation of about 6% to 50%. The dosage form releases about 25% to about 60% of the drugs in the first hour, and not less than about 80% of the drugs in the first 24 hours in an intestinal fluid dissolution media using USP dissolution method II with the paddle speed between 50 rpm and 100 rpm. | 2009-06-25 |
20090162432 | Stable laquinimod preparations - The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid,1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3′-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide. | 2009-06-25 |
20090162433 | METHOD OF TREATMENT - The invention provides the use of darifenacin, or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the reduction of urgency in patients suffering from overactive bladder. | 2009-06-25 |
20090162434 | MESALAZINE TABLET - Disclosed are mesalazine tablets and a method for their preparation. The mesalazine tablets comprise a tablet core, a first coating layer, and a second coating layer. The tablet core comprises mesalazine; the first coating layer comprises a cellulose derivative and/or povidone, and the second coating layer comprises methacrylic acid/methyl methacrylate copolymer and an anti-tack agent. The tablets show a high degree of uniformity and reproducibility and release mesalazine starting at pH 6.8 and are used in the treatment of colorectal diseases. | 2009-06-25 |
20090162435 | MANUFACTURE OF TABLET - The present invention features a method of manufacturing a tablet containing a pharmaceutically active agent by the steps of: (a) adding a powder containing a pharmaceutically-acceptable carrier to a die cavity; (b) injecting a liquid drug composition containing the pharmaceutically active agent into the die cavity such that the liquid drug composition contacts the powder; (c) compressing the combination of the powder and the liquid drug composition within the die cavity to form the tablet; and (d) removing the tablet from the die cavity. | 2009-06-25 |
20090162436 | Compositions and methods for repair of tissues - Biomaterials providing sustained release of growth factor for repair of tissues such as bone and cartilage are disclosed. The biomaterials comprise a proteoglycan derived from domain I of perlecan and a growth factor, and, optionally, collagen. | 2009-06-25 |
20090162437 | Modified self-assembling peptides - The present invention provides a self-assembling peptide comprising: (a) a first amino acid domain that mediates self-assembly, wherein the domain comprises alternating hydrophobic and hydrophilic amino acids that are complementary and structurally compatible and self-assemble into a macroscopic structure when present in unmodified form; and (b) a second amino acid domain that does not mediate self-assembly in isolated form, wherein the second amino acid domain comprises at least one minimal biologically active sequence. Such self-assembling peptides are described herein as “modified self-assembling peptides.” The present invention also provides pharmaceutical compositions, kits and matrices comprising a modified self-assembling peptide, and methods of using and making such compositions, kits and matrices. | 2009-06-25 |
20090162438 | COMPOSITIONS AND METHODS FOR JOINING NON-CONJOINED LUMENS - Disclosed are compositions, methods, and kits for joining together non-conjoined lumens in a patient's body including vascular lumens. More particularly, in various aspects, this invention provides compositions, methods, and kits for joining such non-conjoined lumens, including small lumens typically requiring microsurgical technique | 2009-06-25 |
20090162439 | SILK FIBROIN COATING - The present invention is directed to compositions and methods for preventing or inhibiting biofilm formation on a solid substrate comprising an antimicrobial agent and a biofilm-degrading enzyme embedded in a matrix material. | 2009-06-25 |
20090162440 | SODIUM ALGINATE MICROSPHERE VASCULAR EMBOLUS CONTAINING WATER-SOLUBLE DRUG AND PREPARATION AND APPLICATION THEREOF - The present disclosure relates to a kind of sodium alginate microsphere vascular embolus that contains water-soluble drug and preparation and application thereof. The embolus preparation falls into dry microsphere type and wet one that are made of degradable materials. The drug carrier can be sodium alginate, human serum albumin, chitosan or sodium hyalurate, solidifying and forming microsphere together with calcium ion solution under presence of static charge. The microsphere can have a diameter in the range of 20-1000 μm and can be divided into a wide variety of sizes in case of need. The present disclosure adopts raw materials that are good at mechanical strength, bio-compatibility, bio-degradability and stability. In vitro experiments, animal trials and clinical observations reveal that this embolus is a good targeting medication for embolism treatment and immunochemotherapy, which is safe, effective for the treatment of solid tumors including primary liver cancer, lung cancer, renal tumors, bladder cancer, uterine cancer, ovary cancer, colon carcinoma and rectal cancer. | 2009-06-25 |
20090162441 | PULMONARY DELIVERY IN TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM - A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. The drug is administered at a dose which is at least about two-fold less than the dose required by oral administration. Particles that include the drug can be employed. Preferred particles have a tap density of less than about 0.4 g/cm | 2009-06-25 |
20090162442 | MULTI-PHASIC, NANO-STRUCTURED COMPOSITIONS CONTAINING A COMBINATION OF A FIBRATE AND A STATIN - The present invention discloses a pharmaceutical formulation containing a multi-phasic pharmaceutical composition in an oral dosage form. The multi-phasic pharmaceutical composition contains: (a) a fibrate, or a pharmaceutically acceptable salt, ester, hydrate, or prodrug thereof; (b) a statin, or a pharmaceutically acceptable salt, ester, hydrate, or prodrug thereof; (c) a solvent; (d) a non-miscible liquid; (e) a stabilizer; and (f) water. The fibrate or the statin or both is in a particulate state and/or a solubilized state. Such pharmaceutical formulations are capable of reducing the fed/fast variability and improving oral bioavailability to which a number of active pharmaceutical ingredients are susceptible. The pharmaceutical formulations of the invention, therefore are bioequivalent in fed and fasted states and have improved oral bioavailability. | 2009-06-25 |
20090162443 | COMPOSITIONS AND METHODS FOR REDUCING OR PREVENTING WATER LOSS FROM THE SKIN - Moisturizing compositions comprising microspheres for the purpose of preventing or reducing moisture loss from the skin. | 2009-06-25 |
20090162444 | RALOXIFENE COMPOSITION - A pharmaceutical composition comprising raloxifene or a pharmaceutically acceptable salt thereof, a mixed cellulose excipient, and a disintegrant can be conveniently made. | 2009-06-25 |
20090162445 | Composition for Repair of Defects in Osseous Tissues - Tissue repair compositions, particularly bone repair compositions, containing demineralized bone fragments and homogenized connective tissues. The compositions can be used in the form of an injectable gel, an injectable paste, a paste, a putty, or a rehydratable freeze-dried form. | 2009-06-25 |
20090162446 | ABSORBENT ARTICLE HAVING A STABLE SKIN CARE COMPOSITION - The present invention relates to an absorbent article having a stable skin care composition disposed on its skin-contacting surface. The skin care composition is readily transferable to the skin via normal contact, wearer motion, and/or body heat. Importantly, the skin care composition contains at least one skin care ingredient imparting visible skin benefits to the skin upon transfer to the skin and at least one theological agent for stabilizing the composition such that agglomeration, stratification and/or settling of the composition are minimized. The present invention also relates to a process for making the absorbent articles having a stable skin care composition disposed thereon. | 2009-06-25 |
20090162447 | Spherically Shaped Substances - A particle having a rounded shape and characterized by a substantially smooth surface is disclosed. The particle can be made of a food substance (e.g., nutritional substance or nutraceutical substance), a pharmaceutical (pharmaceutically active ingredient or pharmaceutically acceptable carrier) or a cosmetic substance. | 2009-06-25 |
20090162448 | Metal Carbonate Particles and Methods of Making Thereof - Silver-containing particles, and methods of making silver-containing particles are disclosed. | 2009-06-25 |
20090162449 | STABLE ORAL BENZIMIDAZOLE COMPOSITIONS AND PROCESS OF PREPARATION THEREOF - The present invention relates to stable oral compositions of one or more benzimidazole compounds and processes for their preparation. Also provided are methods for treating various gastrointestinal disorders. | 2009-06-25 |
20090162450 | PHARMACEUTICAL COMPOSITION - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. | 2009-06-25 |
20090162451 | PHARMACEUTICAL COMPOSITIONS - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. | 2009-06-25 |
20090162452 | EB Matrix Production From Animal Tissue And Its Use For Tissue Repair - A method of forming and preserving a bioremodelable, biopolymer scaffold material by subjecting animal tissue to chemical and mechanical processing. In addition to skin tissue, another source of EBM is a blood vessel. EBM may be used for hernia repair, colon, rectal, vaginal and or urethral prolapse treatment; pelvic floor reconstruction; muscle flap reinforcement; lung tissue support; rotator cuff repair or replacement; periosteum replacement; dura repair; pericardial membrane repair; soft tissue augmentation; intervertebral disk repair; and periodontal repair. EBM may also be used as a urethral sling, laminectomy barrier or spinal fusion device. | 2009-06-25 |
20090162453 | COMPOSITION FOR PREVENTING HARMFUL ORGANISMS - There is a harmful organism that cannot be controlled or is difficult to be controlled with the use of a single agent of a compound represented by the general formula (1) according to the invention, an insecticide, a miticide or a fungicide. Accordingly, an object of the invention is to provide a composition for preventing harmful organisms for efficiently controlling such a harmful organism. | 2009-06-25 |
20090162454 | Compositions and Methods for Effecting NAD+ Levels Using A Nicotinamide Phosphoribosyl Tranferase Inhibitor - The present invention relates to methods for decreasing cellular DNA repair in a target patient; decreasing cellular NAD | 2009-06-25 |
20090162455 | FEED FOR FISH - A fish feed comprises carvacrol and/or | 2009-06-25 |
20090162456 | COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE - This invention presented is a composition and method for prevention and treatment of Alzheimer's disease, the composition comprising monacolins, anti-inflammation agents and anti-oxidant compounds is made by the method of the invention. The composition of the invention has effect on prevention and treatment of Alzheimer's disease without noticeable side effects caused to patients. | 2009-06-25 |
20090162457 | RESVERATROL AND/OR GRAPE LEAF EXTRACT AS I. A. ENDURANCE IMPROVER, ANTI-AGING AGENT, MUSCLE STRENGTH IMPROVER - To provide an endurance improver, anti-fatigue agent and anti-aging agent having an ingredient taken for long years as a food, having high safety, easily available, and excellent in processability. An endurance improver, anti-fatigue agent, muscle strength improver, motor performance enhancer and anti-aging agent containing resveratrol and/or grape leaf extract as an effective ingredient. | 2009-06-25 |
20090162458 | COMPOSITIONS AND METHODS FOR INDUCING THE EXPRESSION OF HEAT SHOCK PROTEINS - A nutritional composition comprising at least an effective amount of geranylgeranylacetone or derivative of geranygeranylacetone and/or paeoniflorin or derivative of paeoniflorin and an effective amount of Schisandrin B, wherein the ingredients act substantially simultaneously, via differing mechanism, to enhance the expression of heat shock protein in cells, particularly heat shock protein 72 in skeletal muscle. A method of same is also provided. | 2009-06-25 |
20090162459 | Combination Therapy for Treatment of Patients with Neurological Disorders and Cerebral Infarction - The present invention provides compositions and methods of treating a patient having a condition selected from the group of cerebral stroke, heart stroke, neurodegenerative diseases, brain or nervous system trauma, or neuroplasticity wherein the composition comprises: (i) at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 of: Radix Astragali (milkvetch root or Huang Qi); Rhizoma Salviae Miltiorrhizae root (red sage or Dan Shen); Radix Paeoniae Rubra (red peony or chi shao); Ligusticum Chuanxiong (Chuan Xiong); Rhizoma Notoginseng (Sanqi); Odoriferous Rosewood (Jiang Xiang); Scorpion (Quan Xie); Radix Polygalae (Yuan Zhi); Grassleaf sweetflag (Shi Changpu); Leech (Hirudo or Shuizhi); Ground beetle (Tu Bie Chong); Cow bezoar (calculus Bovis artifactus or Rengong Niuhuang); Gambirplant (ramulus uncariae cum uncis or Gou teng); and (ii) an agent used in Western medicine. | 2009-06-25 |
20090162460 | TIRE MOLD - The invention provides a mold comprising an annular cavity to mold a tire. The mold includes one or more sidewall plates, wherein at least one of said sidewall plates has a recessed channel having an inlet and an outlet, said sidewall plate having an inner surface in engagement with an annular surface of a container plate, wherein the recessed channel and the annular surface of the container plate form a fluid manifold, for circulating a fluid manifold for circulating a fluid medium. Alternatively, the channel may be located inside the sidewall plate. | 2009-06-25 |
20090162461 | TIRE MOLD - The invention provides in a first aspect a segmented mold comprising a plurality of segments arranged to form an annular cavity to mold a tire, the segments further include an inner face for molding the tread, said segments having one or more channels, one or more members received in said one or more channels, said members being joined together to form a fluid manifold for circulating a fluid medium therein. Preferably, the channels are located on the outer radial surface of the segments. The segments may optionally include two or more channels on the outer surface, wherein each channel has a tubular member received therein, wherein the first segment has a first and second tubular member, and the second segment has a first and second tubular member, wherein the first tubular member of the first segment is joined to the second tubular member of the second segment with a first crossmember, and the second tubular member of the first segment is joined to the first tubular member of the second segment with a second cross member, wherein all of said members being joined together to form a fluid manifold for circulating a fluid medium. | 2009-06-25 |
20090162462 | TIRE VULCANIZING DEVICE - A tire vulcanizer is provided in which upper and lower clamp rings can be positioned at a shaping position easily and smoothly with a simple engagement structure. The tier vulcanizer with a vulcanizer body (A) and a shaping unit (B) is configured that the upper and lower clamp rings ( | 2009-06-25 |
20090162463 | TIRE MOLD - A segmented mold comprising a plurality of segments is provided. The segments are arranged to form an annular cavity to mold a tire, the segments comprising an inner face for molding the tread, and an outer radial surface. The mold further includes a plurality of slide blocks located radially outwards of the segments. Each slide block may have flanged ends and an inner cavity for receiving a segment therein. One or more channels are provided between each segment outer surface and the adjacent slide block inner surface forming a fluid passageway, wherein each fluid passageway is joined together by a fluid connector to form a fluid manifold for circulating a fluid medium. Steam may be circulated in the fluid manifold during curing of the mold. | 2009-06-25 |
20090162464 | Mold for Vulcanizing an Unvulcanized Tire Blank - A mold for vulcanizing an unvulcanized tire blank comprises: two axial members each carrying a molding surface for molding a sidewall of the tire, at least one of the axial members being movable between a position for molding the sidewall and a position for unmolding the tire; at least one molding member for molding a channel in a tread of the tire, the molding member being movable between a channel-molding position and a channel-unmolding position; and axial movement means for axially moving the channel-molding member between its molding and unmolding positions. The axial movement means include releasable connection means between the channel-molding member and the axial member. | 2009-06-25 |
20090162465 | Method of Producing a Vulcanizing Mold with a Number of Profile Segments that can be Joined Together to Form a Circumferentially Closed Mold, and Vulcanizing Mold - Profile segments of a vulcanizing mold each contain a basic body which has a profiled forming area on an inner side. A multiplicity of bimaterial rods that are aligned parallel to one another are arranged in each profile segment pressing die such that the longitudinal axes of the bimaterial rods are aligned approximately perpendicular to the forming area surface. The bimaterial rods each contain a core of a filling material disposed parallel to a longitudinal axis. A layer surrounding the core is parallel to the longitudinal axis and is formed of loosely bound—together metal powder, and that, to obtain a green profile segment part, the bimaterial rods are pressed in the pressing die and that the green part is subsequently subjected to a sintering process, by which the filling material can be removed, so that micro channels, that are arranged approximately perpendicular to the forming area remain. | 2009-06-25 |
20090162466 | VARIABLE MULTIPLE PARISON EXTRUSION HEAD HAVING AN ELECTRICALLY OPERATED ACTUATOR - Electrically operated actuator for modifying the thickness of the parisons during extrusion, by means of the usual means which modify the internal cross-section of the discharge mouths of the extrusion head and which are connected to a common cross-member ( | 2009-06-25 |
20090162467 | Resin Sealing/Molding Apparatus - Resin molding apparatus includes in unit, press unit and out unit. The in unit transfers not only pre-molding substrate but also resin material. The press unit includes multiple mold assemblies. The out unit transfers molded substrate having been resin-sealed within the mold assemblies. Further, the resin sealing/molding apparatus includes not only carrier rail but also demounting means and supply means traveling along the carrier rail. Furthermore, multiple press units in the state of being linked with each other are disposed between the in unit and the out unit. | 2009-06-25 |
20090162468 | Controlled Electrospinning of Fibers - An electrospinning apparatus and method for spinning a polymer fiber from a fluid that comprises a polymer, comprises: a plurality of collectors; a jet supply device delivering a quantity of fluid; at least one collector of the plurality of collectors in electrical communication with the jet supply device during at least one time duration, the at least one collector and the jet supply device adapted to form an electric field therebetween and draw the quantity of fluid from the jet supply device toward the at least one collector and form the polymer fiber at the at least one collector device during the at least one time duration; a controller controlling sequence and the at least one time duration of which of each the at least one collector of the plurality of collectors is in electrical communication with the jet supply device at least once during a time period. | 2009-06-25 |
20090162469 | Injection Molding Machine Apparatus and Method of Constructing the Same - A hand operated injection molding machine apparatus constructed from prefabricated sub-assemblies and a desired mold clamping means attached to a main support structure, and then electrically integrated with each other | 2009-06-25 |
20090162470 | PROCESS FOR PRODUCTION OF A SCREW FOR AN EXTRUDER, AND SCREW - At least one section of the screw ( | 2009-06-25 |
20090162471 | Resin-Sealing and Molding Apparatus with Sealing Mechanism and Method of dismounting Contitiuent Part of Die Assembly Fitted Therein - A resin-sealed molding apparatus furnished with sealing means. The sealing means includes upper-die-side ambient air shutoff member fixed to upper-die-side mount base board so as to surround the lateral side of upper die and lower-die-side ambient air shutoff member fixed to lower-die-side mount base board so as to surround the lateral side of lower die. The upper-die-side ambient air shutoff member is fixed to the upper-die-side mount base board by means of upper-die-side fixing tool. The lower-die-side ambient air shutoff member is fixed to the lower-die-side mount base board by means of lower-die-side fixing tool. The upper-die-side ambient air shutoff member and the upper-die-side mount base board are rotatably connected by means of axis member. Only by dismounting of the lower-die-side fixing tool from the lower-die-side mount base board and the lower-die-side ambient air shutoff member, there can be realized the state in which the lower-die-side ambient air shutoff member can be completely dismounted from the lower-die-side mount base board. | 2009-06-25 |
20090162472 | Automotive fuel tank fabrication apparatus - An automotive fuel tank fabrication apparatus is provided. The automotive fuel tank has a blow mold and a built-in part holding unit. The built-in part holding unit includes a plurality of holding rods for holding a built-in part. The holding rods are made to freely advance and retreat in such a manner as to hold the built-in part in a position where the built-in part confronts cavities when the blow mold is opened and to retreat from the blow mold when the blow mold is closed with the built-in part left positioned in an interior of a parison. The holding rods are formed in such a manner that their diameters are reduced as they extend towards distal ends thereof and are inserted into insertion holes formed in the built-in part so as to hold the built-in part. | 2009-06-25 |
20090162473 | Neck Block Cooling - A neck block of a moulding tool for the production of a hollow body preform by means of injection moulding, wherein the neck block has a main body with a shaping surface which is adapted to the external contour of a neck portion of the hollow body preform to be produced and is provided to come into contact in the injection moulding operation with the neck portion of the hollow body preform, wherein furthermore there is provided at least one cooling passage for a cooling fluid which at least portion-wise extends substantially parallel to the shaping surface. The neck block is further provided with an inlet and an outlet and an inlet passage and an outlet passage which connect the inlet and the outlet respectively to the cooling passage. The cooling passage is arranged closer to the shaping surface than the inlet and the outlet. The cooling passage has at least one portion which extends substantially parallel to the shaping surface and which extends within the main body so that the walls thereof are formed by the main body, and a connecting portion which adjoins said portion and the walls of which are formed in part by the main body and in part by a closure element fitted onto the main body. | 2009-06-25 |
20090162474 | 2-METHYLTHIOETHYL-SUBSTITUTED HETEROCYCLES AS FEED ADDITIVES - A chemical compound of the general formula I or II is useful as feed additive: | 2009-06-25 |
20090162475 | Gum Structure Mixing Systems And Methods - A system and method for mixing and forming gum structures is provided. The system may include combinations of continuous and batch mixers arranged generally in series for mixing gum base ingredients with subsequent gum ingredients. In one embodiment, the system and method first forms a gum structure that is not a gum base and then adds a subsequent gum ingredient such that the gum structure is less than a gum base in combination with a subsequent gum ingredient. In other embodiments, the system and method includes forming a gum base in addition to some subsequent gum ingredients that are not quite finished gum. Further, in other embodiments, the system and method may perform some of the mixing of the ingredients at a first location while mixing of further ingredients is performed at a remote location. | 2009-06-25 |
20090162476 | Parallel Gum Component Mixing Systems And Methods - A system and method for mixing and forming gum structures is provided. The system may include combinations of continuous and batch mixers arranged generally in parallel and/or series for mixing gum base ingredients with subsequent gum ingredients. In one embodiment, the system and method first forms a gum structure that is not a gum base and then adds a subsequent gum ingredient such that the gum structure is less than a gum base in combination with a subsequent gum ingredient. In other embodiments, the system and method includes forming a gum base in addition to some subsequent gum ingredients that are not quite finished gum. Further, in other embodiments, the system and method may perform some of the mixing of the ingredients at a first location while mixing of further ingredients is performed at a remote location. | 2009-06-25 |
20090162477 | High yield maize derivatives - A Method for producing triploid corn seeds and plants is described. The method comprises combining two parent inbreds of different ploidy levels, wherein one parent inbred is a tetraploid (4N) and the other parent is a diploid (2N) so as to produce a triploid hybrid corn seed; and cultivating the triploid hybrid corn seed to form a triploid corn plant. Usage of triploid corn plants as an economic source of sugar and ethanol is described, as is the production of molasses, rum and fodder from plant material of the low sterility triploid corn plants. | 2009-06-25 |
20090162478 | HIGH MELT LIPIDS - The presently described technology relates to edible fatty acid ester compositions and methods of preparing the same. The described edible fatty acid ester compositions are prepared by blending a source of fatty acid or fatty acid ester with a polyhydroxy polyol and reacting the components under appropriate conditions to produce an ester or polyester of the polyhydroxy polyol with a melting point of the final composition of greater than about 65° C. The described edible fatty acid esters may be used, for example, to avoid release of a functional ingredient within a food product until temperatures exceed about 65° C. | 2009-06-25 |
20090162479 | PROCESS FOR PRODUCING SOY SAUCE HAVING REDUCED BUSHO-SHU - The present invention relates to a process for producing a soy sauce koji having a reduced Busho-shu which is one of the unpleasant smells of soy sauce, and a soy sauce koji having a reduced Busho-shu obtained by this production process. Specifically, the process for producing a soy sauce koji is characterized by using a combination of a koji mold having a high isobutyric acid productivity and another koji mold having a low isobutyric acid productivity. The present invention also relates to a process for producing a soy sauce having a reduced Busho-shu and a soy sauce obtained by this production process. | 2009-06-25 |
20090162480 | CUTINASE FOR DETOXIFICATION OF FEED PRODUCTS - The present invention relates to a method comprising treatment with cutinase for detoxification of feed products contaminated by the mycotoxin zearalenone. | 2009-06-25 |
20090162481 | Live bacteria product - A live bacteria product including dormant viable bacteria suspended in a liquid carrier. The liquid carrier is sufficiently devoid of moisture so that substantially all of the bacteria will remain in a dormant state for several months or until applied to the target host. The carrier contains mineral oil and polymers and may also include an adsorbent. The product is stored and shipped in a plastic bag and is sprayed onto its target host or the like. The moisture and pH of the target host then activates the bacteria. | 2009-06-25 |
20090162482 | Nutritional Compositions for Bees - A high-protein nutritional composition for bees including protein derived from at least two sources including corn gluten, lipid derived from at least two sources including corn gluten, and carbohydrate. | 2009-06-25 |
20090162483 | SPORTS BEVERAGE AND METHOD OF MAKING - Disclosed herein are sports beverage compositions in liquid drink form for optimizing muscle performance during exercise. The composition is formulated to contain an acid component and a flavor package that minimize off flavors and dry mouthfeel imparted by elevated levels of protein used in the beverage. | 2009-06-25 |
20090162484 | BEVERAGE HAVING A NON-SWEETENING AMOUNT OF A POTENT NATURAL SWEETENER - Beverage products including a non-sweetening amount of a potent natural sweetener are provided. Beverage concentrate compositions including a non-sweetening amount of a potent natural sweetener are also provided. | 2009-06-25 |
20090162485 | WHEY PROTEIN VEHICLE FOR ACTIVE AGENT DELIVERY - The present invention relates to whey protein micelles, a process for the preparation of aggregates of the sane and particularly to their use as a delivery vehicle for active agents in the field of nutrition or cosmetics. | 2009-06-25 |
20090162486 | SPORTS BEVERAGES CONTAINING CARBOHYDRATES - The present invention relates to functional beverages containing carbohydrates, containing at least one protein hydrolysate and isomaltulose and the use of isomaltulose and/or leucrose in a functional beverage containing protein hydrolysate. | 2009-06-25 |
20090162487 | BEVERAGE PRODUCTS AND FLAVOR SYSTEMS HAVING A NON-SWEETENING AMOUNT OF REBAUDIOSIDE A - Beverage products and flavor systems including a non-sweetening amount of rebaudioside A are provided. Beverage concentrate compositions including a non-sweetening amount of rebaudioside A are also provided. In addition, methods for making beverages are provided comprising the steps of providing said flavor system, providing at least one additional beverage ingredient, and mixing the flavor system in an amount of 0.01% to 5.0% by weight of the full strength beverage with the at least one additional beverage ingredient to form a full strength beverage. | 2009-06-25 |
20090162488 | BEVERAGE PRODUCTS AND FLAVOR SYSTEMS HAVING A NON-SWEETENING AMOUNT OF MONATIN - Beverage products and flavor systems including a non-sweetening amount of monatin are provided. Beverage concentrate compositions including a non-sweetening amount of monatin are also provided. In addition, methods for making beverages are provided comprising the steps of providing said flavor system, providing at least one additional beverage ingredient, and mixing the flavor system in an amount of 0.01% to 5.0% by weight of the full strength beverage with the at least one additional beverage ingredient to form a full strength beverage. | 2009-06-25 |
20090162489 | EFFERVESCENT TABLET FOR USE AS AN ADDITIVE IN HOT COFFEE OR HOT WATER AND METHOD OF MAKING SAME - An effervescent tablet for direct use as an additive in hot coffee or hot water includes one or more creamer additives, pH stabilizing agents, effervescence agents, and solubility agents. In one embodiment, the tablet includes dry coffee and, in another embodiment, the tablet excludes it. The creamer additive(s) may be dairy and/or non-dairy. The effervescence agent(s) includes sufficient effervescence to separate the tablet upon placement of the tablet in the hot coffee or water and, in one embodiment, to further create foam on the surface of the coffee so as to yield an instant frothy latte or cappuccino. The pH stabilizing agent(s) stabilizes a pH of the coffee and the solubility agent(s) facilitates expeditious dissolution of the tablet in the coffee or water. Various other ingredients and agents may be included in the tablet to enhance flavor, improve mouth feel, enhance foam production, or achieve other desired characteristics or results. | 2009-06-25 |
20090162490 | CALCIUM-FORTIFIED BEVERAGES AND METHOD OF MAKING THEREOF - A calcium-fortified beverage and method of making the beverage is provided. A calcium source is included that provides about 40% to about 65% of the calcium from calcium lactate and about 35% to about 60% of the calcium is provided from hydroxyapatite. A component may be included for at least substantially masking the aftertaste of the calcium source. | 2009-06-25 |